Comparison of clinical outcomes of inhaled formoterol or fluticasone versus formoterol or mometasone in the patients of bronchial asthma
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20204933Keywords:
Fluticasone/Formoterol, Mometasone/formoterol, FEV1, Bronchial asthmaAbstract
Background: This study was undertaken because of paucity of literature regarding outcomes of inhaled formeterol/fluticasone versus formoterol/mometasone in asthmatic patients.
Methods: Fifty newly (male/female) recruited cases of bronchial asthma were diagnosed on the basis of spirometry. The patients were allocated to two groups viz group A and B. Group-A received mometasone furoate/formoterol (200/10 μg OD) and Group-B received fluticasone/formoterol (200/10 μg OD) respectively. The drugs were administered through metered-dose inhaler (MDI).
Results: The mean FEV1/FVC ratio recorded (64.40±9.01) before starting the treatment has significantly changed to (68.92±8.58) after starting the treatment. Mean forced expiratory volume (47.56±14.73%) noted before the use of bronchodilator also changed to mean FEV1 63.98±15.17. Mean forced expiratory volume recorded before treatment (55.02±5.01) in a group who were treated with formoterol/mometasone combination changed to (72.06±5.86) after treatment. However, the mean forced expiratory volume recorded before treatment 54.92±4.47 in a group who were treated with formoterol/fluticasone combination changed to 75.48±5.03 after the treatment. While comparing the two treatment regimens, it is evident from the results that there is no significant difference in FEV1 between the groups. However, the post bronchodilator FEV1 was significantly (p<0.001) higher among the patient group which were treated with fluticasone/formoterol combination than the group who were treated with mometasone/formoterol combination. No significant adverse effect of either of two regimens was observed thus showing that both the combinations are comparatively safe for use.
Conclusions: This study reveals that both the treatment regimens showed a significant improvement in lung functions without any significant adverse event.
References
Rai SP, Patil AP, Vardhan V, Marwah V, Pethe M, Pandey IM. Best treatment guidelines for bronchial asthma. Med J Armed Forces Ind. 2007;63(3):264-8.
To T, Wang C, Guan J, McLimont S, Gershon AS. What is the lifetime risk of physician-diagnosed asthma in Ontario, Canada? Am J Respir Crit Care Med. 2010;181(4):337-43.
Jindal SK. Bronchial asthma: The Indian scene. Vol. 13, Current Opinion in Pulmonary Medicine. 2007: 8-12.
Jindal SK, Aggarwal AN, Gupta D, Agarwal R, Kumar R, Kaur T, et al. Indian study on epidemiology of asthma, respiratory symptoms and chronic bronchitis in adults (INSEARCH). Int J Tuberc Lung Dis. 2012;16(9):1270-7.
Crompton G. A brief history of inhaled asthma therapy over the last fifty years. Prim Care Respir J. 2006;15:326-31.
Lazarus SC, Boushey HA, Fahy JV, Chinchilli VM, Lemanske Jr RF, Sorkness CA, Kraft M, Fish JE, Peters SP, Craig T, Drazen JM. Long-acting β2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. J Am Med Assoc. 2001;285(20):2583-93.
Lemanske RF, Sorkness CA, Mauger EA, Lazarus SC, Boushey HA, Fahy J V, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: A randomized controlled trial. J Am Med Assoc. 2001;285(20):2594-603.
The Global Initiative for Asthma is supported by unrestricted educational grants from: Visit the GINA website at www.ginaasthma.org GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION Visit the GINA website at www.ginaasthma.org © 2016 Global Initiative for Asthma. Available at: www.ginasthma.org. Accessed on 09 October 2020.
Guidelines for the Diagnosis and Management of Asthma (EPR-3) | NHLBI, NIH. Available at: https://www.nhlbi.nih.gov/health-topics/guidelines-for-diagnosis-management-of-asthma. Accessed on 09 October 2020.
Tan RA, Corren J. Mometasone furoate in the management of asthma: A review. Vol. 4, Therapeutics and Clinical Risk Management. Ther Clin Risk Manag. 2008;4:1201-8.
McKeage K, Keam SJ. Salmeterol fluticasone propionate: A review of its use in asthma. Drugs. 2009;69:1799-828.
Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: Executive summary of the GINA Dissemination Committee Report. Eur J Aller Clinic Immunol. 2004;59:469-78.
Nelson HS. β-Adrenergic bronchodilators. N Eng J Medic. 1995;333(8):499-507.
Barnes PJ. New drugs for asthma. Clinic Experiment Aller. 1996;26(7):738-45.
Anderson GP. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective β2-adrenoceptor agonist bronchodilator. Lif Sci. 1993;52(26):2145-60.
Ullman A, Löfdah1 CG, Melander B, Svedmyr N. Formoterol inhaled as dry powder or via pressurized metered‐dose inhaler in a cumulative dose‐response study. Aller. 1996;51(10):745-8.
Weinstein C, Staudinger H, Scott I, Amar NJ, LaForce C. Dose counter performance of mometasone furoate/formoterol inhalers in subjects with asthma or COPD. Respirat Medic. 2011;105(7):979-88.
Berger WE, Bensch GW, Weinstein SF, Skoner DP, Prenner BM, Shekar T, et al. Bronchodilation with mometasone furoate/formoterol fumarate administered by metered‐dose inhaler with and without a spacer in children with persistent asthma. Pediat Pulmonol. 2014;49(5):441-50.
Pearlman DS, LaForce CF, Kaiser K. Fluticasone/Formoterol combination therapy compared with monotherapy in adolescent and adult patients with mild to moderate asthma. Clinic Therapeut. 2013;35(7):950-66.
Bernstein DI, Hébert J, Cheema A, Murphy KR, Chérrez-Ojeda I, Matiz-Bueno CE, et al. Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthma. Aller Asth Clinic Immunol. 2011;7(1):21.
Frampton JE. Erratum to Mometasone/formoterol inhalation aerosol: in asthma uncontrolled on medium-or high-dose inhaled corticosteroids. Drugs. 2012;72(9):1242.
Meltzer EO, Kuna P, Nolte H, Nayak AS, LaForce C. Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function. Eur Respir J. 2012;39(2):279-89.
Westergaard CG, Porsbjerg C, Backer V. A review of mometasone furoate/formoterol in the treatment of asthma. Expert Opin Pharmacother; 2013;14:339-46.
Nolte H, Pavord I, Backer V, Spector S, Shekar T, Gates D, et al. Dose-dependent anti-inflammatory effect of inhaled mometasone furoate/formoterol in subjects with asthma. Respir Med. 2013;107(5):656-64.
Kosoglou T, Hubbell J, Cutler DL, Johnson-Levonas AO, Xu D, Kantesaria BS, et al. Hypothalamic-pituitary-adrenal axis effects of mometasone furoate/formoterol fumarate vs fluticasone propionate/salmeterol administered through metered-dose inhaler. Chest. 2013;144(6):1795-802.
Berger WE. Mometasone furoate/formoterol in the treatment of persistent asthma. Expert Rev Respir Med. 2011;5(6):739-46.
Pearlman D, Nathan R, Meltzer E, Nolte H, Weinstein S. Effect of mometasone furoate/formoterol combination therapy on nocturnal awakenings in subjects with persistent asthma. Aller Asth Clin Immunol. 2011;7(2):A14.
Bodzenta-Lukaszyk A, Van Noord J, Schröder-Babo W, McAulay K, McIver T. Efficacy and safety profile of fluticasone/formoterol combination therapy compared to its individual components administered concurrently in asthma: A randomised controlled trial. Curr Med Res Opin. 2013;29(5):579-88.
Pertseva T, Dissanayake S, Kaiser K. Superiority of fluticasone propionate/formoterol fumarate versus fluticasone propionate alone in patients with moderate-to-severe asthma: A randomised controlled trial. Curr Med Res Opin. 2013;29(10):1357-69.
Bodzenta-Lukaszyk A, Buhl R, Balint B, Lomax M, Spooner K, Dissanayake S. Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: A randomized, controlled, non-inferiority trial of efficacy and safety. J Asthma. 2012;49(10):1060-70.
Aalbers R, Brusselle G, McIver T, Grothe B, Bodzenta-Lukaszyk A. Onset of bronchodilation with fluticasone/formoterol combination versus fluticasone/salmeterol in an open-label, randomized study. Adv Ther. 2012;29(11):958-69.
Nathan RA, D’Urzo A, Blazhko V, Kaiser K. Safety and efficacy of fluticasone/formoterol combination therapy in adolescent and adult patients with mild-to-moderate asthma: a randomised controlled trial. BMC Pulm Med. 2012;12(1):67.
Dissanayake S, Grothe B, Kaiser K. Fluticasone/formoterol: A new single-aerosol combination therapy for patients with asthma. Respir Med. 2012;106(1)
Corren J, Mansfield LE, Pertseva T, Blahzko V, Kaiser K. Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma. Respir Med. 2013;107(2):180-95.
Mansur AH, Kaiser K. Long-term safety and efficacy of fluticasone/formoterol combination therapy in Asthma. J Aerosol Med Pulm Drug Deliv. 2013;26(4):190-9.
Jain A, Vinod Bhat H, Acharya D. Prevalence of bronchial asthma in rural Indian children: A cross sectional study from South India. Ind J Pediatr. 2010;77(1):31-5.
Barua UK, Saha SK, Ghosh DK, Ruble MMK. Epidemiological Study on Bronchial Asthma at Shaheed Suhrawardy Medical College Hospital, Dhaka. J Shaheed Suhrawardy Med Coll. 2013;5(2):77-80.
Maspero JF, Nolte H, Chérrez-Ojeda I. Long-term safety of mometasone furoateformoterol combination for treatment of patients with persistent asthma. J Asthma. 2010;47(10):1106-15.
Navaratnam P, Friedman HS, Urdaneta E. Mometasone furoate vs fluticasone propionate with salmeterol: Multivariate analysis of resource use and asthma-related charges. Curr Med Res Opin. 2009;25(12):2895-901.
Austin RJH, Maschera B, Walker A, Fairbairn L, Meldrum E, Farrow SN, et al. Mometasone furoate is a less specific glucocorticoid than fluticasone propionate. Eur Respir J. 2002;20(6):1386–92.
Mandl M, Nolop K, Lutsky BN, Aldrey O, Arkinstall W, Baillieau R, et al. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. Ann Alle Asth Immunol. 1997;79(4):370-8.
